Novo Nordisk Insulin Bulk Plant, Kalundborg, Sweden
Key Data:
Project type
Insulin and insulin analogue production and purification facilities
Location
Kalundborg, Sweden
Estimated investment
€337m (first phase), €108m (second phase), €100m (third phase)
Completion
2003–04 (first phase), 2005 (second phase), 2006 (third phase)
Key Players:
Sponsor
Novo Nordisk
Contractor
Novo Nordisk Engineering, Ekato Gruppe
Output Chemicals:
Type
Insulin, insulin analogues, Liraglutide
Volume (total)
>40% of worldwide supply
